Biomarin Pharmaceutical (BMRN) EPS (Basic) Growth (3y) (2012 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) EPS (Basic) Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.31% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn | -8.10% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.10% |
| Mar 31, 2026 | 26.25% |
| Dec 31, 2025 | -465.33% |
| Sep 30, 2025 | -64.69% |
| Jun 30, 2025 | 103.23% |
| Mar 31, 2025 | 13.99% |
| Dec 31, 2024 | 59.75% |
| Sep 30, 2024 | 68.65% |
| Jun 30, 2024 | 99.71% |
| Mar 31, 2024 | 69.99% |
| Dec 31, 2023 | 4.82% |
| Sep 30, 2023 | -63.28% |
| Jun 30, 2023 | 56.68% |
| Mar 31, 2023 | -15.55% |
| Dec 31, 2022 | -26.33% |
| Sep 30, 2022 | -28.40% |
| Jun 30, 2022 | 39.49% |
| Mar 31, 2022 | 59.69% |
| Dec 31, 2021 | -148.58% |
| Sep 30, 2021 | -40.97% |